-
Deutsche Bank Discusses Apixaban From Bristol-Myers Squibb
Thursday, June 23, 2011 - 8:38am | 123Deutsche Bank has a research note on Bristol-Myers Squibb (NYSE: BMY), as it discusses Apixaban. It has a Buy rating and a $31.50 price target on shares. In a note to clients, Deutsche Bank writes, "Xarelto...BI's Pradaxa has superior efficacy to warfarin, but was equivalent on bleeds, while...
-
Morgan Stanley Upgrades Bristol Myers Squibb to Overweight, Raises PT to $34
Thursday, June 23, 2011 - 8:19am | 158Morgan Stanley upgraded its rating on Bristol Myers Squibb (NYSE: BMY) from Equal-weight to Overweight. At the same time, Morgan Stanley raised its price target on the company's stock from $28 to $34. In a research report published today, Morgan Stanley stressed the company's new product apixaban...
-
Jefferies Anticipates Next Key Event in the Oral Anticoagulant Space
Thursday, June 23, 2011 - 8:09am | 121In a report focusing on Bristol-Myers Squibb (NYSE: BMY), Jefferies said that it anticipates the next “key event in the oral anticoagulant space to be the US approval of Xarelto for post-orthopaedic VTE prevention (PDUFA date 4th July), as it would effectively de-risk the approval of the lead...
-
ELIQUIS Meets Primary and Key Secondary Endpoints in Phase 3 ARISTOTLE Study
Thursday, June 23, 2011 - 8:04am | 172Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) announced today topline results of the Phase 3 ARISTOTLE trial of ELIQUIS®. In this study of patients with atrial fibrillation and at least one additional risk factor for stroke, ELIQUIS met the primary efficacy objective of non-...
-
UPDATE: Duncan-Williams Color on Forest Laboratories PT Increase
Thursday, June 23, 2011 - 8:01am | 125Duncan-Williams, which raised its PT on shares of Forest Laboratories Inc. (NYSE: FRX), is providing some color on the stock. “In a recent SEC filing Forest disclosed that the Icahn parties held 7.20% of the outstanding common stock (fourth largest shareholder behind Wellington, Vanguard, and...
-
Deutsche Bank Sees No Catalyst At Eli Lilly Investor Meeting
Thursday, June 23, 2011 - 7:56am | 127Deutsche Bank has a Hold rating and a $38.50 price target on shares of Eli Lilly (NYSE: LLY). In a note to clients, Deutsche Bank writes, "LLY will host its annual investor meeting on June 30th. In anticipation, this report provides an overview of LLY's pipeline, the driver of its performance...
-
Bank of America Merrill Lynch Maintains Buy on Forest Labs
Thursday, June 23, 2011 - 7:35am | 133Bank of America Merrill Lynch is out with its report today on Forest Labs (NYSE: FRX), maintaining Buy. In a note to clients, Bank of America Merrill Lynch writes, "FRX faces big revenue and EPS cliffs after Lexapro goes generic in March 2012, but we believe this is largely factored into valuation...
-
Morgan Stanley Provides Color on Johnson & Johnson, Equal-Weight
Thursday, June 23, 2011 - 7:18am | 138Morgan Stanley provided color on Johnson & Johnson (NYSE: JNJ). In a research report published today, Morgan Stanley commented on the company's new product Xarelto. In the report, Morgan Stanley states, "Positive apixaban data in the ARISTOTLE trial may decrease commercial potential for J...
-
Duncan Williams Raises PT On Forest Laboratories To $45
Thursday, June 23, 2011 - 6:21am | 27Duncan Williams has raised the price target on Forest Laboratories (NYSE: FRX) from $40 to $45 and maintains its Buy rating.
-
Morgan Stanley Upgrades Bristol-Myers Squibb To Overweight, Raises PT To $34
Thursday, June 23, 2011 - 6:15am | 28Morgan Stanley has upgraded Bristol-Myers Squibb (NYSE: BMY) from Equal-weight to Overweight and has raised the price target from $28 to $34.
-
Bristol-Myers Squibb
Wednesday, June 22, 2011 - 7:19pm | 38Bristol-Myers Squibb (BMY) and Pfizer (PFE) said their blood-thinner candidate drug Eliquis met the goals of a phase 3 trial. Bristol-Myers was up 6%. Pfizer climbed 3%.
-
Anacor Pharmaceuticals Announces GSK Has Initiated Two Phase 2 Trials of GSK ‘052 in Complicated Urinary Tract Infections and Complicated Intra-Abdominal Infections
Wednesday, June 22, 2011 - 4:02pm | 227Anacor Pharmaceuticals (NASDAQ: ANAC) announced today that GlaxoSmithKline (GSK) has initiated two separate Phase 2b trials of GSK 2251052, or GSK ‘052 (formerly referred to as AN3365), in complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI). GSK ‘052 is a...
-
Oppenheimer Has Underperform On Cadence Pharmaceuticals
Wednesday, June 22, 2011 - 3:16pm | 152Oppenheimer & Co. has an Underpeform rating on shares of Cadence Pharmaceuticals, Inc. (NASDAQ: CADX). In a note to clients, Oppenheimer & Co. writes, "May OFIRMEV sales are tracking slightly below our expectations, and we expect this trend to continue for the remainder of 2011. Based on...
-
Rodman & Renshaw Reiterates Outperform Rating on Spectrum Pharmaceuticals
Wednesday, June 22, 2011 - 11:06am | 140Rodman & Renshaw is out with a research report this morning, where it reiterates its Outperform rating on Spectrum Pharmaceuticals (NASDAQ: SPPI); it has a $12.00 price target on the stock. The R&R analysts cited a recent meeting with company management, where they came away believing...
-
Goldman Sachs Suggests Buying Put Spreads on Eli Lilly and Company
Wednesday, June 22, 2011 - 10:06am | 151Goldman Sachs is out with a research note this morning, where it suggests that traders buy put spreads on Eli Lilly and Company (NYSE: LLY) ahead of its analyst day. Goldman Sachs Pharma analyst Jami Rubin rates LLY shares Sell and sees 7% downside to her $35 12-mth price target. Importantly, she...